Irene Uceda posted this:
Employee at Consejo Superior de Investigaciones Científicas
Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante
IDIBELL posted this:Drug repurposing for lupus nephritis therapyDrug repurposing for lupus nephritis therapy. Compound X, already approved for human use in other medical indications, administered orally, can be repurposed for lupus nephritis treatment. The principal goal of compound X therapy in lupus nephritis is to normalize renal function or, at least, to prevent the progressive loss of renal function. ✓ Less side effects than the standard of care ✓ Already approved for human in other medical indications (Reprofiling) ✓ Market with 1 approval in last 50 years
Technology Transfer Office
Medical University of Łódź posted this:In vivo and in vitro experimental laboratory complexKeeping animals to research projects as well as own cultures. Cytotoxicity of a medical device in the form of an extract using in vitro assays: NRU, MTT, XTT, colony formation. Research projects in the field of neurology, orthopedics, toxicology, experimental surgery, oncology, metabolic and behavioral research (AnyMAZE, Morris pool, the cage of fear, IntelliCage) Conducting studies using GMOs. Training in procedures on laboratory animals. Renting test equipment.
Radoslaw Rudz posted this:
Licensing Manager at Centre Technology Transfer CITTRU
Technology Transfer OfficeView Profile
Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO) posted this:Predict method of Pregnant Gestational ageDespite the great effort among all sectors of health, the rate of PD remains the "big problem" for obstetricians, neonatologists and other medical specialists, both the difficulties related to the care and complications of those born and their prognosis. long-term. Because PD, in addition to increasing perinatal morbidity and mortality, causes neurological damage and affects development in newborns, there is a great need to identify women at risk of preterm delivery and includes the mechanisms that culminate in PP. method that serves to predict, with clinical and analytical variables, the week of gestation in which delivery will occur.
Jordi Reverter posted this:
Licensing Manager at Institut Català de Nanociència i Nanotecnologia
Technology Transfer OfficeView Profile
Institute of Chemical Research of Catalonia posted this:Optical Quantification of enzymatic activity: a non-invasive diagnosis toolThe platform allows for accurate measurement of the enzymatic activity thanks to the presence of an optical signal that remains unchanged during digestion and serves as a ruler to which modifications of another signal, affected by enzymatic activity, is compared. The platform can be used in small devices, at point of care and in non-invasive diagnostic procedures. The platform is also highly versatile as a simple modification of the particle will allow using it in totally different diagnostic applications.
IMIM Institut Recerca Hospital del Mar posted this:New method for the determination of the risk of atypical fractures in patients treated with bone remodelling inhibitors.Up to date there is not any technology for detecting the risk to suffer atypical fractures related to long-term treatment with bone remodelling inhibitors. The invention will be of usefulness for individualize treatments in patients treated with bone remodelling inhibitors by detecting the individual risk of suffering atypical fractures. The invention is planned to be included into an in-vitro diagnostic tool for the atypical fracture, which will be included into standard disease management protocols and therefore used routinely by physicians prior to and after the prescription of bone remodelling drugs and further osteoporosis drugs. Osteoporosis is a progressive bone disease with a characteristic decrease in bone mass and density which can lead to an increased risk of fracture. There are two types of osteoporosis: •Type 1: most common in women after menopause, named postmenopausal osteoporosis •Type 2: Senile osteoporosis, occurs mostly after age of 75 years and has equally effect in women and in men Based on the WHO diagnostic criteria, approximately 22 million women and 5.5 million men aged between 50 and 84 years had osteoporosis in the European Union (EU) in 2010, whilst osteoporosis can be found in the list of 10 most important diseases named by the WHO. Due to changes in population demography, the number of men and women with osteoporosis might rise from 27.5 million in 2010 to 33.9 million in 2025, corresponding to an increase of 23%. The number of new fractures in the EU in 2010 was estimated at 3,5 million cases, in between these approximately 620.000 hip fractures, 520.000 vertebral fractures, 560.000 forearm fractures and 1.800.000 fractures of i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures. Two thirds of all fractures occurred in women. In 2010, the number of deaths causally related to fractures was estimated at 43.000. The corresponding cost of osteoporosis in the EU, also in 2010 figures, including pharmacological intervention, was estimated at €37 billion out of which costs of treating fractures represented 66%, pharmacological prevention 5% and long term fracture care 29%. The total health burden was estimated at 1 180 000 lost Quality Adjusted Life Years (QALY) for the EU. The total cost in the EU might rise from €98 billion in 2010 to €120 billion Euro in 2025. The use of osteoporosis drugs has increased considerably. Approved pharmacological interventions (bisphosphonates, strontium ranelate, raloxifene, denosumab and parathyroid hormone peptides) are widely available but their use is restricted by reimbursement policies. Alendronate (a bisphosphonate) is the most commonly prescribed agent, accounting for approximately a quarter of the total value of sales. The potential users/partners are pharmaceutical companies, excluding pure generic companies (lacking development resources, relevant lobbying and sales channel to the policy makers and practitioner) selling drugs in the indication osteoporosis
Centre Technology Transfer CITTRU posted this:Monoclonal antibody Miraculum for serological diagnostic in vitroNew IgG antibody suitable for specific agglutination of erythrocytes, particulary for blood typing. The unique IgG3 antibody Miraculum may be a valuable, high-quality, next generation blood typing reagent with extended shelf life. It does not lose its property after freezing. Its production is very efficient and can be more profitable compared to currently used IgM-class antibody. The invention consists in conversion of any non-agglutinating monoclonal antibody that recognizes an antigen on the surface of human erythrocytes into agglutinating molecule. The antibodies obtained in this way can be much more useful than IgM antibodies, which are currently used in agglutination assays.
RAMOT at Tel Aviv University Ltd. posted this:The Ronit Library-A human synthetic combinatorial antibody libraryThe “Ronit 1 Library” is a human synthetic single-chain Fv antibody library of 2?109 independent clones where human complementarity-determining region (CDR) gene fragments of any germ line have been incorporated combinatorially into the appropriate positions of variable-region general frameworks. VH-DP47, VL-DPL3 and VL-DPK22 were used as master frameworks for variable domains of the heavy, lambda light and kappa light chains, respectively. The antibody genes in the library were built on single master frameworks into which diverse CDRs were allowed to recombine. These CDRs were sampled from in vivo-processed gene sequences, thus potentially optimizing the levels of correctly folded and functional molecules, and resulting in a molecule exhibiting a lower immunogenicity compared to naive immunoglobulins. The repertoire of scFvs represented in the “Ronit 1 library” is cloned into pCC16 phagemid vector. As such, the scFvs may be displayed on phage by infection of the host E. coli with a helper phage or may be expressed as soluble scFvs. Project ID : 2-2012-348
RAMOT at Tel Aviv University Ltd. posted this:Optical Labeling and Detection of Hydroxymethylcytosine – a BioMarker for CancerEpigenetic profiling: single-molecule, quantitative optical detection by fluorescent labeling of 5hmC residues. A simple yet highly sensitive 5hmC quantification assay that is compatible with bulk DNA analysis as well as with 5hmC detection on individual DNA molecules. Project ID : 5-2013-462
RAMOT at Tel Aviv University Ltd. posted this:Optical Method for the Diagnosis of Amyloid Diseases, A Biomarker TechnologyA spectroscopic, optical method for early detection of amyloid fibril formation in cerebrospinal fluid, as a non-destructive diagnostic tool for early detection of amyloid diseases. The core recognition motif of A? peptide is the di-phenylalanine (FF) element, which has been found to self-assemble into nanostructures and Quantum Dots. Similar structures have been observed in amyloid fibrils as well, an example below. The amyloid structures are believed to have unique spectrums of optical absorption, photoluminescence, electroluminescence, injection luminescence, thermoluminescence, similar to those of the measured spectrums of self assembling Peptide Nanostructures. Such a distinct, concentration-sensitive measurement, can be used a biomarker for such diseases. Project ID : 5-2013-459
RAMOT at Tel Aviv University Ltd. posted this:Biochip using electrochemical detection of cancer biomarkersBiochip using electrochemical detection of cancer biomarkers Project ID : 8-2012-388